Health-related quality of life and IGF-1 in GH-deficient adult patients on GH replacement therapy: Analysis of the German KIMS data and the Study of Health in Pomerania

European Journal of Endocrinology

Volumn 160, Issue 1, 2009, Pages 17-24

  Moock, Joern ^a   Albrecht, Christin ^a   Friedrich, Nele ^a   Völzke, Henry ^a   Nauck, Matthias ^a   Koltowska Haggström, Maria ^b,c   Kohlmann, Thomas ^a   Wallaschofski, Henri ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b PFIZER INC   (United States)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; SOMATOMEDIN C; HUMAN GROWTH HORMONE;

ADULT; AGE DISTRIBUTION; ARTICLE; CONTROLLED STUDY; FEMALE; GERMANY; GROWTH HORMONE DEFICIENCY; HEALTH STATUS; HEALTH SURVEY; HORMONE SUBSTITUTION; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; QUALITY OF LIFE; SEX DIFFERENCE; TREATMENT RESPONSE; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; HYPOPITUITARISM; METABOLISM; METHODOLOGY; MIDDLE AGED; PSYCHOLOGICAL ASPECT;

ADULT; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; GERMANY; HORMONE REPLACEMENT THERAPY; HUMAN GROWTH HORMONE; HUMANS; HYPOPITUITARISM; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; QUALITY OF LIFE;

EID: 58249093574     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-08-0738     Document Type: Article

References (29)

1. Carroll PV, Christ ER, Bengtsson BA, Carlsson L, Christiansen JS, Clemmons D, Hintz R, Ho K, Laron Z, Sizonenko P, Sonksen PH, Tanaka T & Thorne M. Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. Growth Hormone Research Society Scientific Committee. Journal of Clinical Endocrinology and Metabolism 1998 83 382-395.
2. Carroll PV, Littlewood R, Weissberger AJ, Bogalho P, McGauley G, Sönksen PH & Russell-Jones DL. The effects of two doses of replacement growth hormone on the biochemical, body composition and psychological profiles of growth hormone-deficient adults. European Journal of Endocrinology 1997 137 146-153.
3. van Dam PS. Somatotropin therapy and cognitive function in adults with GHD review. Treatments in Endocrinology 2006 5 159-170.
4. Nyberg F & Burman P. Growth hormone and its receptors in the central nervous system - location and functional significance. Hormone Research 1996 45 18-22.
5. Lai ZN, Emtner M, Roos P & Nyberg F. Characterization of putative growth hormone receptors in human choroid plexus. Brain Research 1991 546 222-226.
6. Drake WM, Coyte D, Camacho-Hübner C, Jivanji NM, Kaltsas G, Wood DF, Trainer PJ, Grossman AB, Besser GM & Monson JP. Optimizing growth hormone replacement therapy by dose titration in hypopituitary adults. Journal of Clinical Endocrinology and Metabolism 1998 83 3913-3919.
7. Murray RD, Skillicorn CJ, Howell SJ, Lissett CA, Rahim A, Smethurst LE & Shalet SM. Influences on quality of life in GH deficient adults and their effect on response to treatment. Clinical Endocrinology 1999 51 565-573.
8. Koltowska-Häggström M, Hennessy S, Mattsson AF, Monson JP & Kind P. Quality of life assessment of growth hormone deficiency in adults (QoL-AGHDA): comparison of normative reference data for the general population of England and Wales with results for adult hypopituitary patients with growth hormone deficiency. Hormone Research 2005 64 46-54.
9. Badia X, Lucas A, Sanmarti A, Roset M & Ulied A. One-year follow-up of quality of life in adults with untreated growth hormone deficiency. Clinical Endocrinology 1998 49 765-771.
10. Koltowska-Häggström M, Mattsson AF, Monson JP, Kind P, Badia X, Casanueva FF, Busschbach J, Koppeschaar HP & Johannsson G. Does long-term GH replacement therapy in hypopituitary adults with GH deficiency normalise quality of life? European Journal of Endocrinology 2006 155 109-119.
11. Wirén L, Whalley D, McKenna S & Wilhelmsen L. Application of a disease-specific, quality-of-life measure (QoL-AGHDA) in growth hormone-deficient adults and a random population sample in Sweden: validation of the measure by rasch analysis. Clinical Endocrinology 2000 52 143-152.
12. Gutiérrez LP, Koltowska-Häggström M, Jönnson PJ, Mattson AF, Svensson D, Westberg B & Luger A. Registries as a tool in evidence-based medicine: example of KIMS (Pfizer International Metabolic Database). Pharmacoepidemiology and Drug Safety 2008 17 90-102.
13. Holmes SJ & Shalet SM. Factors influencing the desire for longterm growth hormone replacement in adults. Clinical Endocrinology 1995 43 151-157.
14. McKenna SP & Doward LC. Quality-of-life assessment of adults with growth hormone deficiency. Implications for drug therapy. PharmacoEconomics 1994 6 434-441.
15. McKenna S & Doward L. Measuring quality of life in adults with growth hormone deficiency. Clinical Endocrinology 1996 45 507-508.
16. McKenna SP, Doward LC, Alonso J, Kohlmann T, Niero M, Prieto L & Wiren L. The QoL-AGHDA: an instrument for the assessment of quality of life in adults with growth hormone deficiency. Quality of Life Research 1999 8 373-383.
17. John U, Greiner B, Hensel E, Lüdemann J, Piek M, Sauer S, Adam C, Born G, Alte D, Greiser E, Haertel U, Hense HW, Haerting J, Willich S & Kessler C. Study of Health in Pommerania (SHIP): a health examination survey in an East German region: objectives and design. Sozial- und Präventivmedizin 2000 46 146-194.
18. Völzke H, Friedrich N, Schipf S, Haring R, Luedemann J, Nauck M, Dorr M, Brabant G & Wallaschofski H. Association between serum insulin-like growth factor-I levels and thyroid disorders in a population-based study. Journal of Clinical Endocrinology and Metabolism 2007 92 4039-4045.
19. Friedrich N, Alte D, Volzke H, Spilcke-Liss E, Lerch MM, Kohlmann T, Nauck M & Wallaschofski H. Reference ranges of serum IGF-I and IGFBP-3 levels in a general adult population: results of the Study of Health in Pomerania (SHIP). Growth Hormone and IGF Research 2008 18 228-233.
20. Bengtsson BA, Abs R, Bennmarker H, Monson JP, Feldt-Rasmussen U, Hernberg-Stahl E, Westberg B, Wilton P & Wuster C. The effects of treatment and the individual responsiveness to growth hormone (GH) replacement therapy in 665 GH-deficient adults. KIMS Study Group and the KIMS International Board. Journal of Clinical Endocrinology and Metabolism 1999 84 3929-3935.
21. Svensson J, Mattsson A, Rosén T, Wirén L, Johannsson G, Bengtsson BA & Koltowska-Häggström M. Swedish KIMS National Board. Three-years of growth hormone (GH) replacement therapy in GH-deficient adults: effects on quality of life, patient-reported outcomes and healthcare consumption. Growth Hormone and IGF Research 2004 14 207-215.
22. Hernberg-Ståhl E, Luger A, Abs R, Bengtsson B-Å, Feldt-Rasmussen U, Wilton P, Westberg B & Monson JP. Healthcare consumption decreases in parallel with improvements in quality of life during GH replacement in hypopituitary adults with GH deficiency. Journal of Clinical Endocrinology and Metabolism 2001 86 5277-5281.
23. Barkan AL. The 'quality of life-assessment of growth hormone deficiency in adults' questionnaire: can it be used to assess quality of life in hypopituitarism? Journal of Clinical Endocrinology and Metabolism 2001 86 1905-1907.
24. Woodhouse LJ, Mukherjee A, Shalet SM & Ezzat S. The influence of growth hormone status on physical impairments, functional limitations, and health-related quality of life in adults. Endocrine Reviews 2006 27 287-317.
25. Svensson J, Finer N, Bouloux P, Bevan J, Jonsson B, Mattsson AF, Lundberg M, Harris PE, Koltowska-Häggström M, Monson JP & KIMS International Board. Growth hormone (GH) replacement therapy in GH deficient adults: predictors of one-year metabolic and clinical response. Growth Hormone and IGF Research 2007 17 67-76.
26. Giusti M, Meineri D, Malagamba D, Cuttica CM, Fattacciu G, Menichini U, Rasore E & Giordano G. Impact of recombinant human growth hormone treatment on psychological profiles in hypopituitary patients with adult-onset growth hormone deficiency. European Journal of Clinical Investigation 1998 28 13-19.
27. Neggers SJ, van Aken MO, de Herder WW, Feelders RA, Janssen JA, Badia X, Webb SM & van der Lely AJ. Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant. Journal of Clinical Endocrinology and Metabolism 2008 98 3853-3859.
28. Rowles SV, Prieto L, Badia X, Shalet SM, Webb SM & Trainer PJ. Quality of life (QOL) in patients with acromegaly is severely impaired: use of a novel measure of QOL: acromegaly quality of life questionnaire. Journal of Clinical Endocrinology and Metabolism 2005 90 3337-3341.
29. Mukherjee A, Adams JE, Smethurst L & Shalet SM. Interdependence of lean body mass and total body water, but not quality of life measures, during low dose GH replacement in GH-deficient adults. European Journal of Endocrinology 2005 153 661-668.